---
title: "The pharmaceutical commercial sector rose sharply in the short term, with HRPC hitting the limit-up"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292551759.md"
description: "The pharmaceutical commercial sector rose sharply in the short term, with HRPC hitting the limit up, followed by C&D INNOSTIC, DSL, Hezong Medicine Easy-To-Buy Pharmaceutical, and Yifeng Pharmacy"
datetime: "2026-07-14T01:53:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292551759.md)
  - [en](https://longbridge.com/en/news/292551759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292551759.md)
generator: "portal-rs"
---

# The pharmaceutical commercial sector rose sharply in the short term, with HRPC hitting the limit-up

The pharmaceutical commercial sector rose sharply in the short term, with HRPC hitting the limit up, followed by C&D INNOSTIC, DSL, Hezong Medicine Easy-To-Buy Pharmaceutical, and Yifeng Pharmacy

### Related Stocks

- [002727.CN](https://longbridge.com/en/quote/002727.CN.md)
- [300937.CN](https://longbridge.com/en/quote/300937.CN.md)
- [600829.CN](https://longbridge.com/en/quote/600829.CN.md)
- [301584.CN](https://longbridge.com/en/quote/301584.CN.md)
- [603233.CN](https://longbridge.com/en/quote/603233.CN.md)
- [603939.CN](https://longbridge.com/en/quote/603939.CN.md)

## Related News & Research

- [Mega IPOs Could be Coming: Here’s How They Might Impact Dividends](https://longbridge.com/en/news/296815476.md)
- [The 30-Year Treasury Now Out-Yields Dividend Stocks by 2.2 Points. History Says What Followed the Last Time.](https://longbridge.com/en/news/296688720.md)
- [This Dividend Stock Is Set for Growth and Its Yield Matches the 10-Year Treasury](https://longbridge.com/en/news/296944835.md)
- [This Canadian Dividend ETF Focuses on High Yields and Dividend Growth](https://longbridge.com/en/news/296874097.md)
- [Be Sure To Check Out SHAPE Australia Corporation Limited (ASX:SHA) Before It Goes Ex-Dividend](https://longbridge.com/en/news/296956714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**